Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study

Hutchings, MartinRadford, JohnAnsell, Stephen M.Illés, ÁrpádSureda, AnnaConnors, Joseph M.Sýkorová, AliceShibayama, HirohikoAbramson, Jeremy S.Chua, Neil S.Friedberg, Jonathan W.Kořen, JanLaCasce, Ann StewardMolina, LysianeEngley, GeraldFenton, KeenanJolin, Hina A.Liu, RachaelGautam, AshishGallamini, Andrea2021-04-192021-04-192021Hematological Oncology. -39 : 2 (2021), p. 185-195. -Hematol. Oncol. - 0278-02320278-0232http://hdl.handle.net/2437/306129Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyidegen nyelvű folyóiratközlemény külföldi lapbanopen access articlehttp://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM093521OrvostudományokKlinikai orvostudományokhttps://onlinelibrary.wiley.com/doi/10.1002/hon.2838http://dx.doi.org/10.1002/hon.28382022-03-23